Central Alerting System
View Alert

Originator: CMO Messaging

From: CMO Messaging

Issue date: Originally issued on 12-Sep-2021 10:27:52. This version was issued on 12-Sep-2021 10:27:52

This alert has been issued to:
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • NHS Trusts (England) - Chief Executive
  • Out of hours contacts

  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • Special Health Authorities
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health

Action category: Action

Title: Interleukin-6 inhibitors (tocilzumab or sarilumab) for patients hospitalised due to COVID-19

Broadcast content:
***31 January 2022. This alert has been updated***

This alert replaces the previous alert CEM/CMO/2021/006 issued on 17th February 2021.

A single UK Interim Clinical Commissioning Policy has now been published, recommending that equal consideration is given to two potential interleukin-6 (IL-6) inhibitor treatment options - tocilizumab or sarilumab - for adult patients (aged 18 years and older) hospitalised due to COVID-19 in accordance with the agreed criteria.  

The combined policy replaces previous separately published policies for sarilumab and tocilizumab respectively.

Additional information: This alert is not relevant to Primary Care.

Alert reference: CEM/CMO/2021/016


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency